JPMorgan Downgrades Nestlé Amid Growth Concerns

Shares of Nestlé faced significant pressure following a key rating change by analysts at JPMorgan. The bank revised its recommendation on the consumer goods giant from “Overweight” to “Neutral,” a move that coincided with a challenging period for the company. In response to the downgrade, Nestlé’s stock fell approximately 4%, with its price settling around €83.75. This level marks a decline of more than 11% from its 52-week high, which was recorded in May 2025.

Growth Trajectory Lags Behind Rivals

The central issue highlighted by JPMorgan’s research is Nestlé’s pace of expansion. The firm’s organic growth is seen as hovering near the bottom of the range when compared to its major European peers in the consumer packaged goods sector. For the full year 2025, Nestlé’s real internal growth reached a modest 0.8%. However, this figure masks a notable acceleration through the year, improving from 0.2% in the first half to 1.4% in the latter six months. Looking ahead to 2026, management has set an organic growth target of 3% to 4%, alongside an anticipated free cash flow exceeding CHF 9 billion. JPMorgan has maintained its price target of 90 Swiss francs.

The bank’s analysts acknowledged that Nestlé’s executive team is actively pursuing several strategic initiatives to stimulate growth. These include portfolio reviews in the Frozen Foods and Waters divisions, ongoing share buyback programs, and the potential strategic use of its stake in L’Oréal. Despite these efforts, JPMorgan indicated that the current strategy is insufficient to warrant a more bullish outlook.

Should investors sell immediately? Or is it worth buying Nestle?

Portfolio Reshaping and Ongoing Headwinds

Nestlé continues to streamline its business portfolio with a clear strategic focus. The company aims to derive roughly 70% of its total sales from three core segments where it holds global leadership: Coffee, Petcare, and Nutrition. In a move to sharpen this focus, Nestlé is gradually transferring its non-US ice cream operations to Froneri. Chief Executive Philipp Navratil has previously characterized this segment as a “distraction.”

These restructuring efforts are occurring against a backdrop of legacy challenges impacting the company’s financials. A recall in its infant nutrition business resulted in costs of CHF 185 million in 2025. Furthermore, management expects to incur additional expenses of approximately CHF 200 million related to this issue in the first quarter of 2026.

One area of relative stability for shareholders is the dividend. For the Annual General Meeting scheduled for April 16, the Board of Directors has proposed a payout of CHF 3.10 per share, an increase of five centimes from the previous year. The ex-dividend date is set for April 20, with payment to follow on April 22. Whether the growth targets for 2026 will be enough to alleviate current market pressures will become clearer with the release of the company’s upcoming quarterly results.